MedTrace Logo

Safety and Efficacy Study of S-309309 in Obese Adults

NCT05925114 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 365

Last updated 2025-04-16

No results posted yet for this study

Summary

The primary objective of this study is to understand the efficacy of S-309309 on the body weight of obese adults.

Conditions

Interventions

DRUG

S-309309

Administered as oral capsules

DRUG

Placebo

Administered as an oral capsule that looks identical to S-309309 capsule

Sponsors & Collaborators

  • Shionogi

    lead INDUSTRY

Principal Investigators

  • Medical Director · Shionogi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-21
Primary Completion
2024-04-15
Completion
2024-05-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05925114 on ClinicalTrials.gov